Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$3.74 - $5.45 $168,337 - $245,304
45,010 New
45,010 $168,000
Q1 2023

May 11, 2023

SELL
$5.89 - $10.52 $10,872 - $19,419
-1,846 Reduced 7.51%
22,741 $156,000
Q4 2022

Feb 14, 2023

BUY
$5.69 - $10.07 $34,788 - $61,567
6,114 Added 33.1%
24,587 $195,000
Q3 2022

Nov 14, 2022

SELL
$7.17 - $13.87 $53,896 - $104,260
-7,517 Reduced 28.92%
18,473 $178,000
Q2 2022

Aug 15, 2022

BUY
$5.86 - $13.23 $73,273 - $165,427
12,504 Added 92.72%
25,990 $188,000
Q1 2022

May 12, 2022

BUY
$10.92 - $16.41 $54,086 - $81,278
4,953 Added 58.05%
13,486 $174,000
Q1 2021

May 12, 2021

BUY
$14.42 - $21.39 $123,045 - $182,520
8,533 New
8,533 $124,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $116M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.